These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 21377644)

  • 1. Microvascular dysfunction in hypertrophic cardiomyopathy: diagnostic role of noninvasive, fully automated quantitative perfusion cardiovascular magnetic resonance imaging.
    Borodzicz-Jazdzyk S; de Mooij GW; van Loon RB; Götte MJW
    Pol Arch Intern Med; 2024 Jan; 134(1):. PubMed ID: 37965961
    [No Abstract]   [Full Text] [Related]  

  • 2. Coronary disorder is not necessarily caused exclusively by coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Usseglio-Polatera E; Riou L; Barone-Rochette G
    Eur Heart J Cardiovasc Imaging; 2024 Mar; 25(4):e145. PubMed ID: 37992055
    [No Abstract]   [Full Text] [Related]  

  • 3. Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier.
    Nollet EE; Westenbrink BD; de Boer RA; Kuster DWD; van der Velden J
    J Am Heart Assoc; 2020 Nov; 9(22):e018641. PubMed ID: 33174505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study.
    Kubo T; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yamanaka S; Iiyama T; Kumagai N; Furuno T; Sugiura T; Kitaoka H
    BMC Cardiovasc Disord; 2015 Jun; 15():53. PubMed ID: 26077897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targets for therapy in sarcomeric cardiomyopathies.
    Tardiff JC; Carrier L; Bers DM; Poggesi C; Ferrantini C; Coppini R; Maier LS; Ashrafian H; Huke S; van der Velden J
    Cardiovasc Res; 2015 Apr; 105(4):457-70. PubMed ID: 25634554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In hypertrophic cardiomyopathy reduction of relative resting myocardial blood flow is related to late enhancement, T2-signal and LV wall thickness.
    Hueper K; Zapf A; Skrok J; Pinheiro A; Goldstein TA; Zheng J; Zimmerman SL; Kamel IR; Abraham R; Wacker F; Bluemke DA; Abraham T; Vogel-Claussen J
    PLoS One; 2012; 7(7):e41974. PubMed ID: 22860042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy.
    Sciagrà R
    Q J Nucl Med Mol Imaging; 2016 Dec; 60(4):354-61. PubMed ID: 27611709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography.
    Timmer SA; Knaapen P
    Eur Heart J Cardiovasc Imaging; 2013 Feb; 14(2):95-101. PubMed ID: 23152441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.
    Timmer SA; Germans T; Brouwer WP; Lubberink M; van der Velden J; Wilde AA; Christiaans I; Lammertsma AA; Knaapen P; van Rossum AC
    Eur J Heart Fail; 2011 Dec; 13(12):1283-9. PubMed ID: 22021246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy.
    Sotgia B; Sciagrà R; Olivotto I; Casolo G; Rega L; Betti I; Pupi A; Camici PG; Cecchi F
    J Nucl Med; 2008 Jul; 49(7):1090-6. PubMed ID: 18552138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging.
    Petersen SE; Jerosch-Herold M; Hudsmith LE; Robson MD; Francis JM; Doll HA; Selvanayagam JB; Neubauer S; Watkins H
    Circulation; 2007 May; 115(18):2418-25. PubMed ID: 17452610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study.
    Knaapen P; Götte MJ; Paulus WJ; Zwanenburg JJ; Dijkmans PA; Boellaard R; Marcus JT; Twisk JW; Visser CA; van Rossum AC; Lammertsma AA; Visser FC
    Radiology; 2006 Aug; 240(2):380-8. PubMed ID: 16864667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed enhancement in hypertrophic cardiomyopathy: comparison with myocardial tagging MRI.
    Kim YJ; Choi BW; Hur J; Lee HJ; Seo JS; Kim TH; Choe KO; Ha JW
    J Magn Reson Imaging; 2008 May; 27(5):1054-60. PubMed ID: 18425835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury.
    Timmer SA; Germans T; Götte MJ; Rüssel IK; Lubberink M; Ten Berg JM; Ten Cate FJ; Lammertsma AA; Knaapen P; van Rossum AC
    Am J Cardiol; 2011 May; 107(10):1522-8. PubMed ID: 21377644
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.